Each NEPA dose provided superior prevention of chemotherapy-induced nausea and vomiting ( CINV ) compared with PALO following highly emetogenic chemotherapy ; however , NEPA300 was the best dose studied , with an advantage over lower doses for all efficacy endpoints .